Carisma Therapeutics (CARM) Institutional Ownership → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free CARM Stock Alerts $1.48 0.00 (0.00%) (As of 05/13/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Carisma Therapeutics (NASDAQ:CARM)CurrentInstitutional OwnershipPercentage44.27%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$7.51MNumber ofInstitutional Sellers(last 12 months)2TotalInstitutional Outflows(last 12 months)$1.54M Get CARM Insider Trade Alerts Want to know when executives and insiders are buying or selling Carisma Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data CARM Institutional Buying and Selling by Quarter Ad TradeSmithThe A.I. story nobody is telling you (Read ASAP)There's been a lot of buzz surrounding A.I. over the past year... Most of it is just hype and speculation. But there's one recent A.I. development you NEED to hear about...Click here to see Louis' new video for yourself. Carisma Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/10/2024 Vanguard Group Inc.1,579,961$3.59M0.0%+0.7%3.803% 5/7/2024 Empowered Funds LLC26,984$61K0.0%-43.9%0.065% 2/14/2024Trustees of The University of Pennsylvania1,252,107$3.67M10.3%-28.9%3.102% 10/13/2023 SG Americas Securities LLC13,653$58K0.0%N/A0.034% 9/21/2023Barclays PLC5,312$47K0.0%N/A0.013% 8/4/2023American International Group Inc.12,834$113K0.0%N/A0.032% 7/27/2023EA Series Trust40,434$355K0.0%N/A0.100% 6/15/2023Trustees of The University of Pennsylvania2,182,812$6.77M6.6%N/A5.422% 5/15/2023 Wittenberg Investment Management Inc.46,703$145K0.1%N/A0.459% 5/12/2023 Deuterium Capital Management LLC51,256$159K0.2%N/A0.504% 5/10/2023 Connor Clark & Lunn Investment Management Ltd.14,796$46K0.0%N/A0.145% 5/3/2023Jump Financial LLC17,542$54K0.0%N/A0.172% 5/1/2023Virtu Financial LLC15,335$48K0.0%N/A0.151% 4/27/2023 Stratos Wealth Partners LTD.19,899$62K0.0%N/A0.195% 4/24/2023 Blodgett Wealth Advisors LLC29,660$92K0.1%N/A0.291% 4/14/2023 BML Capital Management LLC411,398$1.28M1.1%N/A4.041% (Data available from 1/1/2016 forward) CARM Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of CARM shares? During the previous two years, 15 institutional investors and hedge funds held shares of Carisma Therapeutics. The most heavily invested institutionals were Trustees of The University of Pennsylvania ($3.67M), Vanguard Group Inc. ($3.59M), BML Capital Management LLC ($1.28M), EA Series Trust ($355K), Deuterium Capital Management LLC ($159K), Wittenberg Investment Management Inc. ($145K), and American International Group Inc. ($113K).Learn more on CARM's institutional investors. What percentage of Carisma Therapeutics stock is owned by institutional investors? 44.27% of Carisma Therapeutics stock is owned by institutional investors. Learn more on CARM's institutional investor holdings. Which institutional investors have been buying Carisma Therapeutics stock? Of the 14 institutional investors that purchased Carisma Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Trustees of The University of Pennsylvania ($2.18M), BML Capital Management LLC ($411.40K), Deuterium Capital Management LLC ($51.26K), Wittenberg Investment Management Inc. ($46.70K), EA Series Trust ($40.43K), Blodgett Wealth Advisors LLC ($29.66K), and Stratos Wealth Partners LTD. ($19.90K). How much institutional buying is happening at Carisma Therapeutics? Institutional investors have bought a total of 2,872,834 shares in the last 24 months. This purchase volume represents approximately $9.24M in transactions. Which Carisma Therapeutics major shareholders have been selling company stock? The following institutional investors have sold Carisma Therapeutics stock in the last 24 months: Trustees of The University of Pennsylvania ($507.74K), and Empowered Funds LLC ($21.15K). How much institutional selling is happening at Carisma Therapeutics? Institutional investors have sold a total of 528,887 shares in the last 24 months. This volume of shares sold represents approximately $1.54M in transactions. Related Companies: MediciNova Major Shareholders Kronos Bio Major Shareholders Equillium Major Shareholders Viveon Health Acquisition Major Shareholders Aileron Therapeutics Major Shareholders Eagle Pharmaceuticals Major Shareholders Kezar Life Sciences Major Shareholders Checkpoint Therapeutics Major Shareholders Journey Medical Major Shareholders AEON Biopharma Major Shareholders This page (NASDAQ:CARM) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeThe Crypto 9-5 Escape PlanCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe “Next Bitcoin”? 10 CENT Crypto Set to ExplodeTrue Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Carisma Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.